[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100440310":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":37,"centralContacts":41,"locations":46,"responsibleParty":63,"collaborators":10,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":10,"studyType":79,"phases":10,"briefSummary":80,"conditions":81,"keywords":10,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Pregistry","INDUSTRY",[8,15,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Exposed pregnant women",null,"Pregnant or recently pregnant women 18 years of age and older treated with monoclonal antibodies or antiviral drugs indicated for mild, moderate, or severe COVID-19 at any time during pregnancy. For monoclonal antibodies, the exposure period also includes 90 days prior to the first day of the LMP.",[13,14],"Drug: Antiviral Agents","Drug: Monoclonal antibody",{"label":16,"type":10,"description":17,"interventionNames":10},"Active comparator pregnant women","Pregnant women treated with another therapy for mild, moderate, or severe COVID-19",{"label":19,"type":10,"description":20,"interventionNames":10},"Unexposed pregnant women","Pregnant women hospitalized but not treated with a medication specifically indicated for the treatment of mild, moderate, or severe COVID-19",[22,30],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Antiviral Agents","Antiviral medications indicated for the treatment of mild to severe COVID-19",[9],[28,29],"Veklury (remdesivir)","Lagevrio (molnupiravir)",{"type":23,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"Monoclonal antibody","Monoclonal antibodies indicated for the treatment of mild to severe COVID-19",[9],[35,36],"REGEN-COV (casirivimab\u002Fimdevimab)","Xevudy (sotrovimab)",[38],{"name":39,"affiliation":5,"role":40},"Cheryl Renz, MD","PRINCIPAL_INVESTIGATOR",[42],{"name":39,"role":43,"phone":44,"phoneExt":10,"email":45},"CONTACT","18006163791","covid-pr@pregistry.com",[47],{"facility":5,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"RECRUITING","Los Angeles","California","90045","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-118.24368,34.05223,{"lat":58,"lon":57},[61,62],{"name":39,"role":43,"phone":10,"phoneExt":10,"email":10},{"name":39,"role":40,"phone":10,"phoneExt":10,"email":10},{"type":64,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100440310","covid-19-international-drug-pregnancy-registry-100440310",false,"NCT05013632","COVID-19 International Drug Pregnancy Registry","COVID-19 International Drug Pregnancy Registry (COVID-PR)","COVID-PR","Inclusion Criteria:\n\n* Pregnant or recently pregnant (up to 30 days after the end of pregnancy) at time of enrollment\n* Age ≥18 years at time of enrollment\n* With mild to severe COVID-19 during pregnancy\n* Either\n\n  * Treated for COVID-19 with at least one of the medications included in Table 1 during pregnancy. For monoclonal antibodies, the exposure period also includes 90 days prior to the first day of the LMP or\n  * Hospitalized and did not receive any pharmacological treatment specifically indicated for mild, moderate, or severe COVID-19 during pregnancy\n* Resident of a country where a Central Institutional Review Board (IRB) or Ethics Committee provided approval to conduct the study or clearance that approval is not required to conduct the study\n* Signed the informed consent form and submitted the baseline module \"COVID-19 Medications During This Pregnancy\"\n\nExclusion Criteria:\n\n● \\\u003C18 years of age","FEMALE","18 Years","50 Years",{"count":77,"type":78},2000,"ESTIMATED","OBSERVATIONAL","The objective of the COVID-19 International Drug Pregnancy Registry (COVID-PR) is to evaluate obstetric, neonatal, and infant outcomes among women treated with monoclonal antibodies or antiviral drugs indicated for mild, moderate, or severe COVID-19 from the first day of the last menstrual period (LMP) to end of pregnancy. For monoclonal antibodies, the exposure period also includes 90 days prior to the first day of the LMP.",[82],"Covid19","2025-09-22",{"date":85,"type":86},"2025-09-26","ACTUAL",{"date":88,"type":86},"2021-12-01",{"date":90,"type":78},"2027-09-30",{"name":5,"class":6},1]